Promoted Content
Promoted Content

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amlodipine,Atorvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Caduet

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $12,000.0 million Upfront Cash: Undisclosed

            Deal Type: Merger November 16, 2020

            Details:

            Merger of Pfizer's Upjohn with Mylan brings trusted, iconic brands, such as Lipitor, Celebrex and Viagra, and proven commercialization capabilities, including leadership positions in China and other emerging markets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IBUTILIDE FUMARATE

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Premier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 19, 2020

            Details:

            Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fondaparinux

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mylan Inc

            Deal Size: $757.2 million Upfront Cash: $310.4 million

            Deal Type: Acquisition September 08, 2020

            Details:

            Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Icosapent Ethyl

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 07, 2020

            Details:

            Amarin Corporation plc announced that scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) will be presented during the National Lipid Association (NLA) Scientific Sessions 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rosuvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grunenthal

            Deal Size: $350.0 million Upfront Cash: $320.0 million

            Deal Type: Divestment December 01, 2020

            Details:

            Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. The deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atenolol,Chlorthalidone

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 28, 2020

            Details:

            Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem’s Ghaziabad Plant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Heparin Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 18, 2020

            Details:

            Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.